Form 4: uniQure CEO Kapusta Reports Equity Compensation

uniQure N.V.'s CEO, Matthew C. Kapusta, reported the acquisition of restricted share units and stock options, alongside a non-discretionary sale of shares to cover tax withholdings.

Summary

• CEO Matthew C. Kapusta acquired 70,600 Restricted Share Units (RSUs) in uniQure N.V. on March 4, 2026, at a price of $0.
• These RSUs vest in equal annual installments of 1/3 each, beginning on the first anniversary of the grant date, subject to continued employment.
• Kapusta also acquired 113,800 Stock Options with an exercise price of $9.04 on March 4, 2026, which expire on March 4, 2036.
• The Stock Options vest 25% on the first anniversary of the grant date, and 6.25% quarterly thereafter until fully vested, subject to continued employment.
• A total of 14,581 Ordinary Shares were sold on March 4, 2026, at a weighted average price of $9.06 per share (ranging from $9.00 to $9.22).
• This sale was non-discretionary and solely to cover estimated withholding taxes upon the vesting of restricted share units.
• Following these transactions, Kapusta beneficially owns 660,658 Ordinary Shares and 113,800 Stock Options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it indicates continued executive commitment through significant equity grants, aligning management's long-term interests with shareholder value, despite a routine tax-related share sale.

Positives

• The CEO received a significant grant of 70,600 Restricted Share Units and 113,800 Stock Options, indicating continued alignment of management's interests with shareholders.
• The acquisition of stock options at an exercise price of $9.04 suggests a belief in future share price appreciation by the executive.

Negatives

• A sale of 14,581 shares occurred, although it was non-discretionary and solely for tax withholding purposes, not a voluntary divestment.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive compensation packages often include equity awards like RSUs and stock options to incentivize long-term performance and align management interests with shareholder value. This filing reflects a standard practice in the biotechnology sector for retaining and motivating key leadership.

Stakeholder Impact

• Shareholders: The grants align the CEO's interests with long-term shareholder value, as his compensation is tied to the company's stock performance. The tax-related sale is a minor, non-discretionary event with minimal impact.
• Employees: The compensation structure reflects standard practices for executive incentives, which can set a precedent for broader employee equity programs.

Next Steps

• The Restricted Share Units will vest in equal annual installments of 1/3 each, beginning on the first anniversary of the grant date (March 4, 2027).
• The Stock Options will vest 25% on the first anniversary of the grant date (March 4, 2027), and 6.25% quarterly thereafter until fully vested.

Key Dates

Recommendation

The filing details routine executive compensation grants and a non-discretionary tax-related share sale. While the grants align management's interests with long-term shareholder value, there is no new material information within this Form 4 that would warrant a change in investment thesis or a strong buy/sell recommendation. The transactions are expected and do not signal a significant shift in company fundamentals or outlook.

Keywords

uniQure, QURE, Matthew C. Kapusta, Insider Transaction, Form 4, Restricted Share Units, Stock Options, Executive Compensation, Biotechnology